Navigation Links
Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease
Date:4/1/2009

NEW YORK, April 1 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research announced that it would make up to $6.5 million in total funding available under three Critical Challenges research programs designed to accelerate solutions to some of the most difficult hurdles standing in the way of breakthrough therapeutics for PD.

The Critical Challenges funding opportunities focus research efforts on key priority areas in Parkinson's disease drug development. Priority challenges are chosen based on their relevance for addressing broader Foundation goals: define Parkinson's disease and its progression, alter the disease course and reduce its symptoms. The first 2009 Challenges are:

  • Clinicopathological Correlations of Parkinson's Disease will drive projects to understand the clinicopathological correlates of Parkinson's disease using extensive clinical data and postmortem tissue from normal control, PD and related disease subjects. Applicants will collaborate with the Arizona Parkinson's Disease Consortium, an existing MJFF grantee that has developed an exceptional bank of well-characterized postmortem tissue and associated clinical data.
  • Understanding LRRK2 Biology seeks proposals with potential to alter disease course by increasing understanding of the role of the gene LRRK2 in Parkinson's disease and developing essential tools to facilitate and accelerate research and therapeutic development efforts around this promising new therapeutic target. Ideal proposals will work to shed light on critical questions surrounding LRRK2, such as how LRRK2 pathogenic mutations directly lead to in vivo functional and pathological outcomes, and which cellular pathways LRRK2 normally and/or abnormally functions in.
  • Postural Instability and Gait Disorders will drive efforts to better treat PD symptoms by clarifying the pathophysiology and biological correlates of posture and gait dysfunction, which patients report to be one of the most debilitating aspects of living with PD, and which is not well-managed by currently available therapies.

"Through the Critical Challenges programs, MJFF targets research that we believe to have critical relevance to the entire field," said Katie Hood, CEO. "Our in-house research staff, in consultation with the Foundation's scientific advisors, designs each Challenge to address a specific priority area where our funding and expertise can make the greatest difference in speeding scientific developments toward the clinic and patients."

Critical Challenges complement the Foundation's annually recurring Pipeline Programs, which do not identify a specific research priority area to be pursued, but instead provide opportunities for projects at various stages of development to be funded, ensuring that new ideas continue flowing into Parkinson's research. Last November, MJFF announced $11 million in 2009 Pipeline Program funding.

Abbreviated information on the 2009 Critical Challenges follows. Full details are available at www.michaeljfox.org/research.cfm.

Clinicopathological Correlations of Parkinson's Disease 2009

Total available funding: $1.5 million

Deadline: 6 p.m. ET, Tuesday, May 19, 2009

Funding Anticipated: December 2009

Postural Instability and Gait Disturbances 2009

Total available funding: $2 million

Deadline: 6 p.m. ET, Friday, June 5, 2009

Funding Anticipated: December 2009

Understanding LRRK2 Biology 2009

Total available funding: $3 million

Deadline: 6 p.m. ET, Monday, June 1, 2009

Funding Anticipated: December 2009

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded over $142 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016  Palatin Technologies, Inc. ("Palatin") (NYSE MKT: ... previously disclosed underwritten public offering of units with ... sole book-running manager, Roth Capital Partners acted as ... co-manager for the offering. "This financing ... proceeds, allowing us to continue advancing bremelanotide for ...
(Date:12/7/2016)... Md. , Dec. 7, 2016  Northwest ... or the "Company"), a biotechnology company developing DCVax® ... announced that the Nasdaq Staff has not accepted ... of Listing Rules previously reported, and the Company ... withdraw the Company,s common stock from listing on ...
(Date:12/7/2016)... , December 7, 2016 ... Trial Management System (CTMS) Market, by Components (Software, ... Site), End-users (Pharmaceutical and Biotechnology Companies, Clinical Research ... Share, Size and Forecast to 2022", published by ... system (CTMS) market is expected to grow at ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ... now promoting to the US market its advanced highly customizable contact technology solutions. ... ODU TURNTAC®. These advanced technologies are ideal for a wide range of applications ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers Insurance ... residents in the Sacramento/Folsom region, is initiating a charity event to raise support ... Choice Another Chance treatment center in Sacramento works to provide area teens and ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... A. Kevin ... owners and families throughout the Five Boroughs, is launching a charity drive to raise ... to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working closely ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the ... and Your Health on Voice of America, declared on her radio program in November ... the fact that when these bullies attack leaders in corporate America, they are trying ...
Breaking Medicine News(10 mins):